NEULANDLAB Stock Overview
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for NEULANDLAB from our risk checks.
Neuland Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹7,536.80 |
| 52 Week High | ₹7,790.00 |
| 52 Week Low | ₹1,981.20 |
| Beta | 1.02 |
| 1 Month Change | 18.04% |
| 3 Month Change | 34.45% |
| 1 Year Change | 276.96% |
| 3 Year Change | 209.12% |
| 5 Year Change | 966.48% |
| Change since IPO | 7,833.47% |
Recent News & Updates
There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19
We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Recent updates
There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Neuland Laboratories (NSE:NEULANDLAB) Has A Pretty Healthy Balance Sheet
Mar 15Can You Imagine How Elated Neuland Laboratories' (NSE:NEULANDLAB) Shareholders Feel About Its 391% Share Price Gain?
Feb 28Don't Ignore The Fact That This Insider Just Sold Some Shares In Neuland Laboratories Limited (NSE:NEULANDLAB)
Feb 12Neuland Laboratories Limited (NSE:NEULANDLAB) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 04Neuland Laboratories Limited's (NSE:NEULANDLAB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Feb 03Read This Before Selling Neuland Laboratories Limited (NSE:NEULANDLAB) Shares
Jan 18
If You Like EPS Growth Then Check Out Neuland Laboratories (NSE:NEULANDLAB) Before It's Too Late
Jan 01Is Neuland Laboratories Limited (NSE:NEULANDLAB) Popular Amongst Insiders?
Dec 14Did Business Growth Power Neuland Laboratories' (NSE:NEULANDLAB) Share Price Gain of 117%?
Nov 26Shareholder Returns
| NEULANDLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.09% | -0.5% | 1.4% |
| 1Y | 277.0% | 55.3% | 46.1% |
Return vs Industry: NEULANDLAB exceeded the Indian Pharmaceuticals industry which returned 53.7% over the past year.
Return vs Market: NEULANDLAB exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| NEULANDLAB volatility | |
|---|---|
| NEULANDLAB Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: NEULANDLAB's share price has been volatile over the past 3 months.
Volatility Over Time: NEULANDLAB's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,554 | Davuluri Rao | www.neulandlabs.com |
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services.
Neuland Laboratories Limited Fundamentals Summary
| NEULANDLAB fundamental statistics | |
|---|---|
| Market cap | ₹96.75b |
| Earnings (TTM) | ₹3.17b |
| Revenue (TTM) | ₹15.81b |
30.5x
P/E Ratio6.1x
P/S RatioIs NEULANDLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEULANDLAB income statement (TTM) | |
|---|---|
| Revenue | ₹15.81b |
| Cost of Revenue | ₹7.62b |
| Gross Profit | ₹8.18b |
| Other Expenses | ₹5.01b |
| Earnings | ₹3.17b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 247.13 |
| Gross Margin | 51.77% |
| Net Profit Margin | 20.06% |
| Debt/Equity Ratio | 8.9% |
How did NEULANDLAB perform over the long term?
See historical performance and comparison